Brussels, 27 January 2026 — Today, we at P3lab (doing business as neuroClues) are launching our crowdfunding campaign on LITA. We’re inviting you to become a shareholder of a European MedTech with the ambition to revolutionize neurology
Who is neuroClues?
We are a MedTech company aiming to develop the stethoscope of the brain: a medical device that provides objective eye movement biomarkers. These biomarkers offer clinicians complementary information, helping to refine and objectify diagnosis and to improve the monitoring of neurological disorders.
Why does this matter?
1 in 3 people will develop a neurological disorder.
In Parkinson’s disease, for example:
- The number of people affected is expected to double by 2040.
- 1 in 5 people diagnosed with Parkinson’s disease will receive a revised diagnosis within two years.
- By the time patients receive their diagnosis, they have already lost up to 70% of their dopaminergic cells, limiting treatment effectiveness.
Why the eyes?
Your eyes are the window to your brain.
Decades of research have shown that oculomotor biomarkers reflect brain function and can provide powerful diagnostic insights.
Over 80,000 scientific articles on eye movements have been published in the past 60 years. This body of work clearly demonstrates the close connection between the central nervous system and eye movements.
Yet, despite their strong clinical potential, eye‑movement analysis remains largely underused in clinical practice, mainly because current eyetracking solutions are complex to implement and operate.
We want to change that.
Our Crowdfunding on LITA
For the first time, we’re opening our journey to everyone… not just professional investors. You can join us and help bring this technology into the hands of even more clinicians.
This campaign is part of the closing of our Serie A funding round.
What is LITA, and why this platform?
LITA.co is a European impact investment platform that allows everyday people to invest in companies that create positive social change.
We chose LITA because:
- it supports mission-driven innovation,
- it allows the public to become real shareholders,
- and it fits perfectly with our vision of making neurological care more accessible
Led by a Visionary Team
The neuroClues team brings together around 30 professionals with complementary expertise, distributed across the headquarters and manufacturing facility in Louvain-la-Neuve (Belgium), an office in Bordeaux, and an office in Paris within iPEPS at La Pitié-Salpêtrière (France’s first incubator dedicated to brain diseases). The team is supported by an experienced leadership, led by Antoine Pouppez, CEO, with 15 years of experience in the pharmaceutical and medical industries. Technology is overseen by Pierre Daye, CTO and research expert, while scientific expertise is provided by Pierre Pouget, Research Director at the Brain Institute (CNRS). Commercial strategy is driven by Bart Stulens, who brings over 25 years of experience in the pharmaceutical and medtech sectors, including at Medtronic.
Join the mission
You likely know someone affected by a neurological disorder : a parent, a friend, a colleague. Earlier and more accurate diagnosis allows for better patient care.
If you want to support European innovation in medical technology and help provide neurologists with the right tools to diagnose and monitor neurological disorders, contribute to advancing our ambition of becoming the “stethoscope of the brain” by joining the campaign on LITA.
